Extracellular Vesicle-Based Detection of Pancreatic Cancer

Due to a grim prognosis, there is an urgent need to detect pancreatic ductal adenocarcinoma (PDAC) prior to metastasis. However, reliable diagnostic imaging methods or biomarkers for PDAC or its precursor lesions are still scarce. ADAM8, a metalloprotease-disintegrin, is highly expressed in PDAC tis...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cell and developmental biology Vol. 9; p. 697939
Main Authors Verel-Yilmaz, Yesim, Fernández, Juan Pablo, Schäfer, Agnes, Nevermann, Sheila, Cook, Lena, Gercke, Norman, Helmprobst, Frederik, Jaworek, Christian, Pogge von Strandmann, Elke, Pagenstecher, Axel, Bartsch, Detlef K., Bartsch, Jörg W., Slater, Emily P.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 23.07.2021
Subjects
Online AccessGet full text
ISSN2296-634X
2296-634X
DOI10.3389/fcell.2021.697939

Cover

Abstract Due to a grim prognosis, there is an urgent need to detect pancreatic ductal adenocarcinoma (PDAC) prior to metastasis. However, reliable diagnostic imaging methods or biomarkers for PDAC or its precursor lesions are still scarce. ADAM8, a metalloprotease-disintegrin, is highly expressed in PDAC tissue and negatively correlates with patient survival. The aim of our study was to determine the ability of ADAM8-positive extracellular vesicles (EVs) and cargo microRNAs (miRNAs) to discriminate precursor lesions or PDAC from healthy controls. In order to investigate enrichment of ADAM8 on EVs, these were isolated from serum of patients with PDAC ( n = 52), precursor lesions ( n = 7) and healthy individuals ( n = 20). Nanoparticle Tracking Analysis and electron microscopy indicated successful preparation of EVs that were analyzed for ADAM8 by FACS. Additionally, EV cargo analyses of miRNAs from the same serum samples revealed the presence of miR-720 and miR-451 by qPCR and was validated in 20 additional PDAC samples. Statistical analyses included Wilcoxon rank test and ROC curves. FACS analysis detected significant enrichment of ADAM8 in EVs from patients with PDAC or precursor lesions compared to healthy individuals ( p = 0.0005). ADAM8-dependent co-variates, miR-451 and miR-720 were also diagnostic, as patients with PDAC had significantly higher serum levels of miR-451 and lower serum levels of miR-720 than healthy controls and reached high sensitivity and specificity (AUC = 0.93 and 1.00, respectively) to discriminate PDAC from healthy control. Thus, detection of ADAM8-positive EVs and related cargo miR-720 and miR-451 may constitute a specific biomarker set for screening individuals at risk for PDAC.
AbstractList Due to a grim prognosis, there is an urgent need to detect pancreatic ductal adenocarcinoma (PDAC) prior to metastasis. However, reliable diagnostic imaging methods or biomarkers for PDAC or its precursor lesions are still scarce. ADAM8, a metalloprotease-disintegrin, is highly expressed in PDAC tissue and negatively correlates with patient survival. The aim of our study was to determine the ability of ADAM8-positive extracellular vesicles (EVs) and cargo microRNAs (miRNAs) to discriminate precursor lesions or PDAC from healthy controls. In order to investigate enrichment of ADAM8 on EVs, these were isolated from serum of patients with PDAC (n = 52), precursor lesions (n = 7) and healthy individuals (n = 20). Nanoparticle Tracking Analysis and electron microscopy indicated successful preparation of EVs that were analyzed for ADAM8 by FACS. Additionally, EV cargo analyses of miRNAs from the same serum samples revealed the presence of miR-720 and miR-451 by qPCR and was validated in 20 additional PDAC samples. Statistical analyses included Wilcoxon rank test and ROC curves. FACS analysis detected significant enrichment of ADAM8 in EVs from patients with PDAC or precursor lesions compared to healthy individuals (p = 0.0005). ADAM8-dependent co-variates, miR-451 and miR-720 were also diagnostic, as patients with PDAC had significantly higher serum levels of miR-451 and lower serum levels of miR-720 than healthy controls and reached high sensitivity and specificity (AUC = 0.93 and 1.00, respectively) to discriminate PDAC from healthy control. Thus, detection of ADAM8-positive EVs and related cargo miR-720 and miR-451 may constitute a specific biomarker set for screening individuals at risk for PDAC.Due to a grim prognosis, there is an urgent need to detect pancreatic ductal adenocarcinoma (PDAC) prior to metastasis. However, reliable diagnostic imaging methods or biomarkers for PDAC or its precursor lesions are still scarce. ADAM8, a metalloprotease-disintegrin, is highly expressed in PDAC tissue and negatively correlates with patient survival. The aim of our study was to determine the ability of ADAM8-positive extracellular vesicles (EVs) and cargo microRNAs (miRNAs) to discriminate precursor lesions or PDAC from healthy controls. In order to investigate enrichment of ADAM8 on EVs, these were isolated from serum of patients with PDAC (n = 52), precursor lesions (n = 7) and healthy individuals (n = 20). Nanoparticle Tracking Analysis and electron microscopy indicated successful preparation of EVs that were analyzed for ADAM8 by FACS. Additionally, EV cargo analyses of miRNAs from the same serum samples revealed the presence of miR-720 and miR-451 by qPCR and was validated in 20 additional PDAC samples. Statistical analyses included Wilcoxon rank test and ROC curves. FACS analysis detected significant enrichment of ADAM8 in EVs from patients with PDAC or precursor lesions compared to healthy individuals (p = 0.0005). ADAM8-dependent co-variates, miR-451 and miR-720 were also diagnostic, as patients with PDAC had significantly higher serum levels of miR-451 and lower serum levels of miR-720 than healthy controls and reached high sensitivity and specificity (AUC = 0.93 and 1.00, respectively) to discriminate PDAC from healthy control. Thus, detection of ADAM8-positive EVs and related cargo miR-720 and miR-451 may constitute a specific biomarker set for screening individuals at risk for PDAC.
Due to a grim prognosis, there is an urgent need to detect pancreatic ductal adenocarcinoma (PDAC) prior to metastasis. However, reliable diagnostic imaging methods or biomarkers for PDAC or its precursor lesions are still scarce. ADAM8, a metalloprotease-disintegrin, is highly expressed in PDAC tissue and negatively correlates with patient survival. The aim of our study was to determine the ability of ADAM8-positive extracellular vesicles (EVs) and cargo microRNAs (miRNAs) to discriminate precursor lesions or PDAC from healthy controls. In order to investigate enrichment of ADAM8 on EVs, these were isolated from serum of patients with PDAC ( n = 52), precursor lesions ( n = 7) and healthy individuals ( n = 20). Nanoparticle Tracking Analysis and electron microscopy indicated successful preparation of EVs that were analyzed for ADAM8 by FACS. Additionally, EV cargo analyses of miRNAs from the same serum samples revealed the presence of miR-720 and miR-451 by qPCR and was validated in 20 additional PDAC samples. Statistical analyses included Wilcoxon rank test and ROC curves. FACS analysis detected significant enrichment of ADAM8 in EVs from patients with PDAC or precursor lesions compared to healthy individuals ( p = 0.0005). ADAM8-dependent co-variates, miR-451 and miR-720 were also diagnostic, as patients with PDAC had significantly higher serum levels of miR-451 and lower serum levels of miR-720 than healthy controls and reached high sensitivity and specificity (AUC = 0.93 and 1.00, respectively) to discriminate PDAC from healthy control. Thus, detection of ADAM8-positive EVs and related cargo miR-720 and miR-451 may constitute a specific biomarker set for screening individuals at risk for PDAC.
Due to a grim prognosis, there is an urgent need to detect pancreatic ductal adenocarcinoma (PDAC) prior to metastasis. However, reliable diagnostic imaging methods or biomarkers for PDAC or its precursor lesions are still scarce. ADAM8, a metalloprotease-disintegrin, is highly expressed in PDAC tissue and negatively correlates with patient survival. The aim of our study was to determine the ability of ADAM8-positive extracellular vesicles (EVs) and cargo microRNAs (miRNAs) to discriminate precursor lesions or PDAC from healthy controls. In order to investigate enrichment of ADAM8 on EVs, these were isolated from serum of patients with PDAC (n = 52), precursor lesions (n = 7) and healthy individuals (n = 20). Nanoparticle Tracking Analysis and electron microscopy indicated successful preparation of EVs that were analyzed for ADAM8 by FACS. Additionally, EV cargo analyses of miRNAs from the same serum samples revealed the presence of miR-720 and miR-451 by qPCR and was validated in 20 additional PDAC samples. Statistical analyses included Wilcoxon rank test and ROC curves. FACS analysis detected significant enrichment of ADAM8 in EVs from patients with PDAC or precursor lesions compared to healthy individuals (p = 0.0005). ADAM8-dependent co-variates, miR-451 and miR-720 were also diagnostic, as patients with PDAC had significantly higher serum levels of miR-451 and lower serum levels of miR-720 than healthy controls and reached high sensitivity and specificity (AUC = 0.93 and 1.00, respectively) to discriminate PDAC from healthy control. Thus, detection of ADAM8-positive EVs and related cargo miR-720 and miR-451 may constitute a specific biomarker set for screening individuals at risk for PDAC.
Author Bartsch, Jörg W.
Pogge von Strandmann, Elke
Bartsch, Detlef K.
Nevermann, Sheila
Slater, Emily P.
Helmprobst, Frederik
Jaworek, Christian
Schäfer, Agnes
Cook, Lena
Pagenstecher, Axel
Fernández, Juan Pablo
Gercke, Norman
Verel-Yilmaz, Yesim
AuthorAffiliation 3 Department of Neuropathology, Philipps University Marburg , Marburg , Germany
5 Institute for Tumorimmunology, Philipps University Marburg , Marburg , Germany
1 Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg , Marburg , Germany
4 Core Facility-Mouse Pathology and Electron Microscopy (MPEM), Philipps University Marburg , Marburg , Germany
2 Department of Neurosurgery, Philipps University Marburg , Marburg , Germany
AuthorAffiliation_xml – name: 5 Institute for Tumorimmunology, Philipps University Marburg , Marburg , Germany
– name: 4 Core Facility-Mouse Pathology and Electron Microscopy (MPEM), Philipps University Marburg , Marburg , Germany
– name: 3 Department of Neuropathology, Philipps University Marburg , Marburg , Germany
– name: 2 Department of Neurosurgery, Philipps University Marburg , Marburg , Germany
– name: 1 Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg , Marburg , Germany
Author_xml – sequence: 1
  givenname: Yesim
  surname: Verel-Yilmaz
  fullname: Verel-Yilmaz, Yesim
– sequence: 2
  givenname: Juan Pablo
  surname: Fernández
  fullname: Fernández, Juan Pablo
– sequence: 3
  givenname: Agnes
  surname: Schäfer
  fullname: Schäfer, Agnes
– sequence: 4
  givenname: Sheila
  surname: Nevermann
  fullname: Nevermann, Sheila
– sequence: 5
  givenname: Lena
  surname: Cook
  fullname: Cook, Lena
– sequence: 6
  givenname: Norman
  surname: Gercke
  fullname: Gercke, Norman
– sequence: 7
  givenname: Frederik
  surname: Helmprobst
  fullname: Helmprobst, Frederik
– sequence: 8
  givenname: Christian
  surname: Jaworek
  fullname: Jaworek, Christian
– sequence: 9
  givenname: Elke
  surname: Pogge von Strandmann
  fullname: Pogge von Strandmann, Elke
– sequence: 10
  givenname: Axel
  surname: Pagenstecher
  fullname: Pagenstecher, Axel
– sequence: 11
  givenname: Detlef K.
  surname: Bartsch
  fullname: Bartsch, Detlef K.
– sequence: 12
  givenname: Jörg W.
  surname: Bartsch
  fullname: Bartsch, Jörg W.
– sequence: 13
  givenname: Emily P.
  surname: Slater
  fullname: Slater, Emily P.
BookMark eNp9kctuFDEQRS0URMKQD2DXSzY9cdluP1ggwZBApEiwAMTOKj8mOOppB7sHwd_jzkSIsGDlkqvuqcd9So6mPEVCngNdc67N2dbHcVwzymAtjTLcPCInjBnZSy6-Hv0VH5PTWm8opcAGNWj-hBxzwaUGIU_Iy_Ofc8EFtR-xdF9iTX6M_RusMXRv4xz9nPLU5W33ESdfIs7Jd5sWxvKMPN7iWOPp_bsiny_OP23e91cf3l1uXl_1Xgg29wy1lpQOEkQMMAhgQSt0SnJOnWGaA8UQwAwhUNR-aAsZdN47JwUY5_iKXB64IeONvS1ph-WXzZjs3Ucu1xbLvIxtPRdANYDSwgkZqGZGSNSIjiKE1nJFXh1Yt3u3i8HHqW0_PoA-zEzpm73OP6xuJ6OgGuDFPaDk7_tYZ7tLdTkfTjHvq2XDYKRiSrNWCodSX3KtJW7_tAFqFwvtnYV2sdAeLGwa9Y_GpxkXC9o0afyP8jdjfaGO
CitedBy_id crossref_primary_10_3390_diagnostics13040766
crossref_primary_10_1016_j_saa_2025_125745
crossref_primary_10_1038_s41551_023_01033_1
crossref_primary_10_1158_2767_9764_CRC_21_0147
crossref_primary_10_1186_s12951_022_01641_0
crossref_primary_10_1016_j_canlet_2025_217546
crossref_primary_10_1016_j_mcpro_2024_100830
crossref_primary_10_3390_ijms241210203
crossref_primary_10_3390_ijms25063406
crossref_primary_10_3390_ijms23041976
crossref_primary_10_1016_j_cytogfr_2023_08_003
crossref_primary_10_1039_D3CC02982D
crossref_primary_10_3389_fcell_2023_1130823
crossref_primary_10_1186_s12935_024_03456_5
crossref_primary_10_3390_cells13010003
crossref_primary_10_1111_febs_17034
Cites_doi 10.1038/nature14581
10.1016/j.canlet.2008.12.028
10.1111/j.1582-4934.2007.00082.x
10.18632/oncotarget.3598
10.3322/caac.21590
10.3390/jpm11020077
10.1038/ncomms7175
10.3390/jcm7100295
10.1007/s12020-014-0202-
10.1590/1678-4324-2018160730
10.1146/annurev-cellbio-101512-122326
10.3390/jpm11020113
10.1016/j.bbamcr.2017.05.027
10.1073/pnas.1521230113
10.1155/2017/2381482
10.3892/mmr.2017.7732
10.1038/srep30110
10.1186/s13058-016-0699-z
10.1002/0471143030.cb0322s30
10.3390/biomedicines8120581
10.1515/hsz-2018-0396
10.1155/2019/1639854
10.1182/blood-2012-08-449306
ContentType Journal Article
Copyright Copyright © 2021 Verel-Yilmaz, Fernández, Schäfer, Nevermann, Cook, Gercke, Helmprobst, Jaworek, Pogge von Strandmann, Pagenstecher, Bartsch, Bartsch and Slater.
Copyright © 2021 Verel-Yilmaz, Fernández, Schäfer, Nevermann, Cook, Gercke, Helmprobst, Jaworek, Pogge von Strandmann, Pagenstecher, Bartsch, Bartsch and Slater. 2021 Verel-Yilmaz, Fernández, Schäfer, Nevermann, Cook, Gercke, Helmprobst, Jaworek, Pogge von Strandmann, Pagenstecher, Bartsch, Bartsch and Slater
Copyright_xml – notice: Copyright © 2021 Verel-Yilmaz, Fernández, Schäfer, Nevermann, Cook, Gercke, Helmprobst, Jaworek, Pogge von Strandmann, Pagenstecher, Bartsch, Bartsch and Slater.
– notice: Copyright © 2021 Verel-Yilmaz, Fernández, Schäfer, Nevermann, Cook, Gercke, Helmprobst, Jaworek, Pogge von Strandmann, Pagenstecher, Bartsch, Bartsch and Slater. 2021 Verel-Yilmaz, Fernández, Schäfer, Nevermann, Cook, Gercke, Helmprobst, Jaworek, Pogge von Strandmann, Pagenstecher, Bartsch, Bartsch and Slater
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fcell.2021.697939
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ : Directory of Open Access Journals [open access]
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2296-634X
ExternalDocumentID oai_doaj_org_article_c3410811784b46d082946a8aab0a1d76
PMC8343017
10_3389_fcell_2021_697939
GrantInformation_xml – fundername: Deutsche Forschungsgemeinschaft
  grantid: BA-1606/4-1
GroupedDBID 53G
5VS
9T4
AAFWJ
AAYXX
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RPM
7X8
5PM
ID FETCH-LOGICAL-c442t-2a886005614ed15412d87ab76330b928310add195dd0a8c50219abccbb6419bb3
IEDL.DBID M48
ISSN 2296-634X
IngestDate Wed Aug 27 01:25:32 EDT 2025
Thu Aug 21 18:08:12 EDT 2025
Thu Sep 04 20:24:23 EDT 2025
Tue Jul 01 03:20:31 EDT 2025
Thu Apr 24 22:51:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c442t-2a886005614ed15412d87ab76330b928310add195dd0a8c50219abccbb6419bb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Cheng Wang, Nanjing University, China; Xinlei Li, Nationwide Children’s Hospital, United States
Edited by: Jeffrey David Galley, The Ohio State University, United States
These authors have contributed equally to this work
This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fcell.2021.697939
PMID 34368146
PQID 2559672782
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_c3410811784b46d082946a8aab0a1d76
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8343017
proquest_miscellaneous_2559672782
crossref_primary_10_3389_fcell_2021_697939
crossref_citationtrail_10_3389_fcell_2021_697939
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-07-23
PublicationDateYYYYMMDD 2021-07-23
PublicationDate_xml – month: 07
  year: 2021
  text: 2021-07-23
  day: 23
PublicationDecade 2020
PublicationTitle Frontiers in cell and developmental biology
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Colombo (B3) 2014; 30
Jaworek (B8) 2021; 11
Das (B5) 2016; 18
Siegel (B16) 2020; 70
Sumrin (B19) 2018; 61
Zonari (B24) 2013; 122
Kowal (B10) 2016; 113
Shimoda (B15) 2017
Sperveslage (B17) 2014; 46
Théry (B20) 2006; 30
Bartsch (B2) 2018; 7
Gospodarowicz (B6) 2017
Melo (B11) 2015; 523
Zhang (B23) 2017; 16
Keller (B9) 2009; 278
Schlomann (B14) 2015; 6
Cufaro (B4) 2019; 2019
Su (B18) 2016; 6
Minciacchi (B12) 2015; 6
Badovinac (B1) 2021; 11
Schlomann (B13) 2019; 400
Valkovskaya (B21) 2007; 11
Guo (B7) 2017; 2017
Yee (B22) 2020; 8
References_xml – volume: 523
  start-page: 177
  year: 2015
  ident: B11
  article-title: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
  publication-title: Nature
  doi: 10.1038/nature14581
– volume: 278
  start-page: 73
  year: 2009
  ident: B9
  article-title: Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes.
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2008.12.028
– volume: 11
  start-page: 1162
  year: 2007
  ident: B21
  article-title: ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer.
  publication-title: J. Cell Mol. Med.
  doi: 10.1111/j.1582-4934.2007.00082.x
– volume: 6
  start-page: 11327
  year: 2015
  ident: B12
  article-title: Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles.
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3598
– volume: 70
  start-page: 7
  year: 2020
  ident: B16
  article-title: Cancer statistics, 2020.
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21590
– volume: 11
  year: 2021
  ident: B1
  article-title: Plasma extracellular vesicle characteristics correlate with tumor differentiation and predict overall survival in patients with pancreatic ductal adenocarcinoma undergoing surgery with curative intent.
  publication-title: J. Pers. Med.
  doi: 10.3390/jpm11020077
– volume: 6
  year: 2015
  ident: B14
  article-title: ADAM8 as a drug target in pancreatic cancer.
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms7175
– volume: 7
  year: 2018
  ident: B2
  article-title: The combination of MiRNA-196b, LCN2, and TIMP1 is a potential set of circulating biomarkers for screening individuals at risk for familial pancreatic cancer.
  publication-title: J. Clin. Med.
  doi: 10.3390/jcm7100295
– volume: 46
  start-page: 226
  year: 2014
  ident: B17
  article-title: Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas.
  publication-title: Endocrine
  doi: 10.1007/s12020-014-0202-
– volume: 61
  year: 2018
  ident: B19
  article-title: Exosomes as biomarker of cancer.
  publication-title: Braz. Arch. Biol. Technol.
  doi: 10.1590/1678-4324-2018160730
– volume: 30
  start-page: 255
  year: 2014
  ident: B3
  article-title: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.
  publication-title: Annu. Rev. Cell Dev. Biol.
  doi: 10.1146/annurev-cellbio-101512-122326
– year: 2017
  ident: B6
  publication-title: TNM Classification of Malignant Tumors.
– volume: 11
  year: 2021
  ident: B8
  article-title: Cohort analysis of ADAM8 expression in the PDAC tumor stroma.
  publication-title: J. Pers. Med.
  doi: 10.3390/jpm11020113
– start-page: 1989
  year: 2017
  ident: B15
  article-title: Metalloproteinases in extracellular vesicles.
  publication-title: Biochim. Biophys. Acta Mol. Cell Res.
  doi: 10.1016/j.bbamcr.2017.05.027
– volume: 113
  start-page: E968
  year: 2016
  ident: B10
  article-title: Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.1521230113
– volume: 2017
  year: 2017
  ident: B7
  article-title: MiR-451 promotes cell proliferation and metastasis in pancreatic cancer through targeting CAB39.
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2017/2381482
– volume: 16
  start-page: 9256
  year: 2017
  ident: B23
  article-title: MicroRNA-720 inhibits pancreatic cancer cell proliferation and invasion by directly targeting cyclin D1.
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2017.7732
– volume: 6
  year: 2016
  ident: B18
  article-title: Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of microRNAs 155 and 125b2 transfection using nanoparticle delivery systems.
  publication-title: Sci. Rep.
  doi: 10.1038/srep30110
– volume: 18
  year: 2016
  ident: B5
  article-title: miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
  publication-title: Breast Cancer Res.
  doi: 10.1186/s13058-016-0699-z
– volume: 30
  start-page: 3.22.21
  year: 2006
  ident: B20
  article-title: Isolation and characterization of exosomes from cell culture supernatants and biological fluids.
  publication-title: Curr. Protoc. Cell Biol.
  doi: 10.1002/0471143030.cb0322s30
– volume: 8
  year: 2020
  ident: B22
  article-title: Extracellular vesicles as potential biomarkers for early detection and diagnosis of pancreatic cancer.
  publication-title: Biomedicines
  doi: 10.3390/biomedicines8120581
– volume: 400
  start-page: 801
  year: 2019
  ident: B13
  article-title: Metalloprotease inhibitor profiles of human ADAM8 in vitro and in cell-based assays.
  publication-title: Biol. Chem.
  doi: 10.1515/hsz-2018-0396
– volume: 2019
  year: 2019
  ident: B4
  article-title: Extracellular vesicles and their potential use in monitoring cancer progression and therapy: the contribution of proteomics.
  publication-title: J. Oncol.
  doi: 10.1155/2019/1639854
– volume: 122
  start-page: 243
  year: 2013
  ident: B24
  article-title: A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice.
  publication-title: Blood
  doi: 10.1182/blood-2012-08-449306
SSID ssj0001257583
Score 2.2834332
Snippet Due to a grim prognosis, there is an urgent need to detect pancreatic ductal adenocarcinoma (PDAC) prior to metastasis. However, reliable diagnostic imaging...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 697939
SubjectTerms ADAM8
Cell and Developmental Biology
extracellular vesicles
miRNA
pancreatic cancer
serum biomarkers
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bS8MwFA4iCL6IV5w3Kvgk1KVp2ia-ubkxBMUHJ3sLubQoSCe7gP57z0m2sb7oi69tQtLvpOeSnHyHkKskNeBEyCR2aVHE3HEb66oSMdXM5lmVi8JfFH58ygdD_jDKRmulvjAnLNADB-DaFtQsxduQghueO7wKynMttDZUJ67wZNtU0rVgKuyugBsi0nCMCVGYbFe4EQ7xIEtucgmLUjYMkefrbziZzRTJNZvT3yU7C2cxuguT3CMbZb1PtkL5yO8Dctv7gl44IuaSRq_lFJvFHTBMLrovZz7Lqo7GVfQMsvXeoY26KObJIRn2ey_dQbyohRBbztksZlqIPPB2lg7cnoQ5UWgD2iGlRjIsFwaaKpGZc1QLm8F3Sm2sNSbniTQmPSKb9bguj0mUmcQgXS8AZME0GVlWWCZTMlYJzRhtEboERtkFUTjWq_hQEDAglspjqRBLFbBsketVl8_AkvFb4w6ivWqIBNf-AYhdLcSu_hJ7i1wuZaXgh8AxdF2O51OFMRIeLwvWIkVDiI0Rm2_q9zdPrS1SDhqvOPmPKZ6Sbfxq3Ahm6RnZnE3m5Tl4MDNz4RfrD8H47BM
  priority: 102
  providerName: Directory of Open Access Journals
Title Extracellular Vesicle-Based Detection of Pancreatic Cancer
URI https://www.proquest.com/docview/2559672782
https://pubmed.ncbi.nlm.nih.gov/PMC8343017
https://doaj.org/article/c3410811784b46d082946a8aab0a1d76
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-yjo28jK1rWfZRPOhTwZkty7I0GGPtGsJgYw_N6JvQh90Ngr05KST__e5kp8RQ9rBXW4fQ3Un3u9PpDuA0zSyCCJXGPiuKmHvuYlNVMk4McyKvhCzCQ-Gv38R8wb9c59cj2LW36hm4ute1o35Si3Y53fzZfsQN_4E8TrS37yqKcaOrx9KpUKhv6gE8DNdFlMnXo_0u5ILYRGbd3eb9lGN4nFFN9gCI9wxVqOc_AKHDFMo9mzR7Ck96MBl96qT_DEZlfQiPuvaS2-fw_nKDVDQ55ZpGP8oVDYvP0XD56HO5DllYddRU0XeUfUCPLrogNWiPYDG7vLqYx32vhNhxztYxM1KKrq5n6REWpczLwlg8PbLEKkbtxPAkS1XufWKky3HJyljnrBU8VdZmx3BQN3X5AqLcppbK-SKvHJouq8qK2mgqxippGEsmkOwYo11fSJz6WSw1OhTEVh3YqomtumPrBM7uSH53VTT-NficuH03kApghw9Ne6P7_aQdWt-EHslKbrnw9EKYCyONsYlJfSEm8HYnK40bhuYwddncrjT5UHT9LNkEioEQBzMO_9S_fobS2xK1A8-wl_9N-QrGtFSKDrPsNRys29vyDcKatT0J4YCToLJ_AcZV9tA
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Extracellular+Vesicle-Based+Detection+of+Pancreatic+Cancer&rft.jtitle=Frontiers+in+cell+and+developmental+biology&rft.au=Verel-Yilmaz%2C+Yesim&rft.au=Fern%C3%A1ndez%2C+Juan+Pablo&rft.au=Sch%C3%A4fer%2C+Agnes&rft.au=Nevermann%2C+Sheila&rft.date=2021-07-23&rft.pub=Frontiers+Media+S.A&rft.eissn=2296-634X&rft.volume=9&rft_id=info:doi/10.3389%2Ffcell.2021.697939&rft_id=info%3Apmid%2F34368146&rft.externalDocID=PMC8343017
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-634X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-634X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-634X&client=summon